Joseph Thome
Stock Analyst at TD Cowen
(1.54)
# 3,512
Out of 5,124 analysts
19
Total ratings
43.75%
Success rate
-5.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Hold | $50 → $63 | $75.96 | -17.06% | 3 | Nov 5, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $10 | $5.83 | +71.53% | 1 | Oct 31, 2025 | |
| MIRM Mirum Pharmaceuticals | Initiates: Buy | $95 | $78.99 | +20.27% | 1 | Sep 24, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $78.41 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $31.12 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $487.25 | -17.91% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $30.34 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $27.98 | +21.52% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $3.47 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $1.62 | - | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $44.82 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.41 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $182.64 | -28.82% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.99 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.28 | - | 1 | Nov 23, 2021 |
PTC Therapeutics
Nov 5, 2025
Maintains: Hold
Price Target: $50 → $63
Current: $75.96
Upside: -17.06%
Ardelyx
Oct 31, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $5.83
Upside: +71.53%
Mirum Pharmaceuticals
Sep 24, 2025
Initiates: Buy
Price Target: $95
Current: $78.99
Upside: +20.27%
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $78.41
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $31.12
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $487.25
Upside: -17.91%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $30.34
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $27.98
Upside: +21.52%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $3.47
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.62
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $44.82
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.41
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $182.64
Upside: -28.82%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $8.99
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.28
Upside: -